Immunic (NASDAQ:IMUX) Stock Moved Up to Strong-Buy by Zacks Research

Zacks Research upgraded shares of Immunic (NASDAQ:IMUX) from a hold rating to a strong-buy rating in a report published on Wednesday morning,Zacks reports.

IMUX has been the subject of a number of other research reports. Wall Street Zen cut shares of Immunic from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Roth Capital restated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Immunic in a report on Thursday, September 10th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Immunic in a research note on Thursday, September 10th. Four equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunic presently has an average rating of “Buy” and an average price target of $35.43.

Immunic Trading Down 3.5%

NASDAQ IMUX opened at $7.22 on Wednesday. The company has a market cap of $98.48 million, a PE ratio of -1.65 and a beta of 1.45. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43. The stock has a 50 day moving average of $11.23 and a 200-day moving average of $12.52.

Immunic (NASDAQ:IMUX) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36. As a group, sell-side analysts predict that Immunic will post -3.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Immunic

Large investors have recently modified their holdings of the stock. CTC Alternative Strategies Ltd. bought a new stake in shares of Immunic during the 1st quarter worth about $27,000. ADAR1 Capital Management LLC bought a new position in Immunic in the 1st quarter valued at about $33,000. Bank of America Corp DE raised its holdings in Immunic by 80,724.2% in the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after acquiring an additional 143,689 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Immunic in the 1st quarter valued at about $187,000. Finally, Simplify Asset Management Inc. acquired a new stake in Immunic during the first quarter worth approximately $487,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.